Menu Search
Equities

CanSino Biologics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
688185:SHH

CanSino Biologics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)63.90
  • Today's Change-0.93 / -1.43%
  • Shares traded1.54m
  • 1 Year change+4.09%
  • Beta1.8693
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year CanSino Biologics Inc grew revenues 137.01% from 357.08m to 846.34m while net income improved from a loss of 1.48bn to a smaller loss of 378.88m.
Gross margin78.80%
Net profit margin-14.62%
Operating margin-14.76%
Return on assets-1.86%
Return on equity-2.84%
Return on investment-2.29%
More ▼

Cash flow in CNYView more

In 2024, cash reserves at CanSino Biologics Inc fell by 490.29m. However, Cash Flow from Investing totalled 2.46m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 167.29m for operations while cash used for financing totalled 334.18m.
Cash flow per share--
Price/Cash flow per share--
Book value per share21.37
Tangible book value per share20.03
More ▼

Balance sheet in CNYView more

CanSino Biologics Inc has a Debt to Total Capital ratio of 22.42%, a higher figure than the previous year's 19.23%.
Current ratio3.62
Quick ratio3.29
Total debt/total equity0.289
Total debt/total capital0.2242
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.